After securing more than $60 million in funding from Immatics Biotechnologies GmbH (Immatics) and the Cancer Prevention and Research Institute of Texas (CPRIT), The University of Texas MD Anderson Cancer Center announced it will join with Immatics in a brand-new venture: the formation of ImmaticOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.